Folate  	Folate  	 NNP	B-NP
in  	in  	 IN	O
depression 	depression 	 NN	O
:  	:  	 :	O
efficacy 	efficacy 	 CD	O
,  	,  	 ,	O
safety 	safety 	 NN	O
,  	,  	 ,	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
formulations 	formulations 	 NNS	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
issues  	issues  	 NNS	I-NP
Supplementation  	Supplementation  	 NNP	I-NP
with  	with  	 IN	O
folate  	folate  	 NNS	B-NP
may  	may  	 MD	O
help  	help  	 VB	O
reduce  	reduce  	 VB	O
depressive  	depressive  	 JJ	B-NP
symptoms 	symptoms 	 NNS	I-NP
.  	.  	 .	O
Folate 	Folate 	 NNP	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
naturally  	naturally  	 RB	O
occurring  	occurring  	 VBG	B-NP
B  	B  	 NNP	I-NP
vitamin 	vitamin 	 NN	I-NP
,  	,  	 ,	O
is  	is  	 VBZ	O
needed  	needed  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
brain  	brain  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
synthesis  	synthesis  	 NN	O
of  	of  	 IN	O
norepinephrine 	norepinephrine 	 NN	B-NP
,  	,  	 ,	O
serotonin 	serotonin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
dopamine 	dopamine 	 NN	B-NP
.  	.  	 .	O
Three  	Three  	 CD	O
forms  	forms  	 NNS	O
of  	of  	 IN	O
folate  	folate  	 NNS	B-NP
are  	are  	 VBP	O
commonly  	commonly  	 RB	O
used 	used 	 VBN	O
:  	:  	 :	O
folic  	folic  	 JJ	B-NP
acid 	acid 	 NN	I-NP
,  	,  	 ,	O
5-methyltetrahydrofolate  	5-methyltetrahydrofolate  	 NNP	B-NP
( 	( 	 -LRB-	O
5-MTHF 	5-MTHF 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
also  	also  	 RB	O
known  	known  	 VBN	O
as  	as  	 IN	O
methylfolate  	methylfolate  	 NN	B-NP
and  	and  	 CC	O
L-methylfolate 	L-methylfolate 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
folinic  	folinic  	 JJ	B-NP
acid 	acid 	 NN	I-NP
.  	.  	 .	O
Some  	Some  	 DT	O
forms  	forms  	 NNS	O
may  	may  	 MD	O
be  	be  	 VB	O
more  	more  	 JJR	O
bioavailable  	bioavailable  	 NN	B-NP
than  	than  	 IN	O
others  	others  	 NNS	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
genetic  	genetic  	 JJ	B-NP
polymorphism  	polymorphism  	 NN	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
those  	those  	 DT	O
who  	who  	 WP	O
take  	take  	 VBP	O
particular  	particular  	 JJ	O
medications  	medications  	 NN	O
or  	or  	 CC	O
use  	use  	 NN	B-NP
alcohol 	alcohol 	 NN	I-NP
.  	.  	 .	O
Folic  	Folic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
augmentation  	augmentation  	 NN	I-NP
in  	in  	 IN	O
depressed  	depressed  	 JJ	O
patients  	patients  	 NNS	O
may  	may  	 MD	O
reduce  	reduce  	 VB	O
residual  	residual  	 JJ	B-NP
symptoms 	symptoms 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
5-MTHF  	5-MTHF  	 JJ	O
formulation  	formulation  	 NN	O
indicated  	indicated  	 VBD	O
efficacy  	efficacy  	 VBN	O
as  	as  	 IN	O
adjunctive  	adjunctive  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
or  	or  	 CC	O
monotherapy  	monotherapy  	 NN	B-NP
in  	in  	 IN	O
reducing  	reducing  	 VBG	O
depressive  	depressive  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
normal  	normal  	 JJ	O
and  	and  	 CC	O
low  	low  	 JJ	O
folate  	folate  	 JJ	B-NP
levels 	levels 	 NNS	I-NP
,  	,  	 ,	O
improving  	improving  	 VBG	O
cognitive  	cognitive  	 JJ	B-NP
function  	function  	 NN	I-NP
and  	and  	 CC	O
reducing  	reducing  	 VBG	O
depressive  	depressive  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
in  	in  	 IN	O
elderly  	elderly  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
dementia  	dementia  	 NN	B-NP
and  	and  	 CC	O
folate  	folate  	 JJ	B-NP
deficiency 	deficiency 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
reducing  	reducing  	 VBG	B-NP
depressive  	depressive  	 NNS	I-NP
and  	and  	 CC	O
somatic  	somatic  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
depression  	depression  	 NN	O
and  	and  	 CC	O
alcoholism 	alcoholism 	 NN	O
.  	.  	 .	O
Adjunctive  	Adjunctive  	 JJ	B-NP
folinic  	folinic  	 JJ	I-NP
acid  	acid  	 NN	I-NP
reduced  	reduced  	 VBD	O
depressive  	depressive  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
were  	were  	 VBD	O
partially  	partially  	 RB	O
responsive  	responsive  	 JJ	O
or  	or  	 CC	O
nonresponsive  	nonresponsive  	 JJ	O
to  	to  	 TO	O
a  	a  	 DT	O
selective  	selective  	 JJ	B-NP
serotonin  	serotonin  	 JJ	I-NP
reuptake  	reuptake  	 JJ	I-NP
inhibitor 	inhibitor 	 NN	I-NP
.  	.  	 .	O
Evidence  	Evidence  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
folate  	folate  	 NN	B-NP
in  	in  	 IN	O
improving  	improving  	 VBG	O
cognitive  	cognitive  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
is  	is  	 VBZ	O
equivocal 	equivocal 	 VBN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
most  	most  	 JJS	O
studies  	studies  	 NNS	O
used  	used  	 VBN	O
folic  	folic  	 JJ	B-NP
acid 	acid 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
studies  	studies  	 NNS	O
reviewed  	reviewed  	 VBN	O
have  	have  	 VBP	O
limitations  	limitations  	 NNS	O
and 	and 	 CC	O
,  	,  	 ,	O
historically 	historically 	 RB	O
,  	,  	 ,	O
concerns  	concerns  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
raised  	raised  	 VBN	O
about  	about  	 IN	O
the  	the  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
folate  	folate  	 NN	B-NP
in  	in  	 IN	O
increasing  	increasing  	 VBG	B-NP
cancer  	cancer  	 NN	I-NP
risk 	risk 	 NN	I-NP
,  	,  	 ,	O
masking  	masking  	 VBG	B-NP
B 	B 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
12 	12 	 CD	I-NP
)  	)  	 -RRB-	I-NP
deficiency 	deficiency 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
worsening  	worsening  	 VBG	O
depressive  	depressive  	 JJ	B-NP
symptoms 	symptoms 	 NNS	I-NP
,  	,  	 ,	O
folate  	folate  	 NN	B-NP
is  	is  	 VBZ	O
generally  	generally  	 RB	O
well  	well  	 RB	O
tolerated 	tolerated 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
5-MTHF  	5-MTHF  	 NNP	O
may  	may  	 MD	O
be  	be  	 VB	O
less  	less  	 RBR	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
incur  	incur  	 VB	O
some  	some  	 DT	O
of  	of  	 IN	O
these  	these  	 DT	O
risks 	risks 	 NNS	O
.  	.  	 .	O
Several  	Several  	 JJ	O
forms  	forms  	 NNS	O
of  	of  	 IN	O
folate  	folate  	 NNS	B-NP
appear  	appear  	 VBP	O
to  	to  	 TO	O
be  	be  	 VB	O
safe  	safe  	 JJ	O
and  	and  	 CC	O
efficacious  	efficacious  	 NN	O
in  	in  	 IN	O
some  	some  	 DT	O
individuals  	individuals  	 NNS	O
with  	with  	 IN	O
major  	major  	 JJ	O
depressive  	depressive  	 JJ	B-NP
disorder 	disorder 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
more  	more  	 JJR	O
information  	information  	 NN	O
is  	is  	 VBZ	O
needed  	needed  	 VBN	O
about  	about  	 IN	O
dosage  	dosage  	 NN	O
and  	and  	 CC	O
populations  	populations  	 NNS	O
most  	most  	 RBS	O
suited  	suited  	 VBN	O
to  	to  	 TO	O
folate  	folate  	 VB	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
